COVID-19 and SIC (!)

J Vasc Surg. 2020 Sep;72(3):1148-1150. doi: 10.1016/j.jvs.2020.05.047. Epub 2020 Jun 1.

Authors

Ilja Nevzorov¹, Riikka Tulamo², Anders Albäck², Riitta Lassila³

Affiliations

¹ Faculty of Medicine, University of Helsinki, Helsinki, Finland.
² Department of Vascular Surgery, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.
³ Coagulation Disorders Unit, University of Helsinki, Departments of Haematology and Clinical Chemistry (HUSLAB Laboratory Services), Comprehensive Cancer Center, Helsinki University Hospital and Research Program in Systems Oncology, Faculty of Medicine, University of Helsinki and Helsinki University, Faculty of Medicine, Research Program in Oncology, Helsinki, Finland; Aplagon Oy, Helsinki, Finland.

No abstract available

Publication types

Letter

MeSH terms

Anticoagulants / administration & dosage
Betacoronavirus / pathogenicity*
COVID-19
Coronavirus Infections / blood
Coronavirus Infections / complications*
Coronavirus Infections / diagnosis
Coronavirus Infections / virology
Disseminated Intravascular Coagulation / diagnosis*
Disseminated Intravascular Coagulation / drug therapy
Disseminated Intravascular Coagulation / etiology
Disseminated Intravascular Coagulation / mortality
Fibrin Fibrinogen Degradation Products / analysis
Humans
Pandemics
Pneumonia, Viral / blood
Pneumonia, Viral / complications*
Pneumonia, Viral / diagnosis
Pneumonia, Viral / virology
Prognosis
Prothrombin Time
SARS-CoV-2
Sepsis / blood
Sepsis / complications*
Sepsis / immunology
Sepsis / virology
Severity of Illness Index

Substances

Anticoagulants
Fibrin Fibrinogen Degradation Products
fibrin fragment D